On Tuesday, an expert panel advising the Food and Drug Administration (FDA) on the use of MDMA, or ecstasy, in combination with talk therapy to treat post-traumatic stress disorder rejected the treatment. The group voted 9 to 2 on its effectiveness and 10 to 1 on whether its benefits outweigh its risks. While the FDA will still vote separately on MDMA, it generally follows the recommendation of its advisors, so its unlikely the novel treatment will gain approval.
